Metabolic dysfunction-associated fatty liver disease (MAFLD) is a chronic condition that
affects nearly one billion people globally, characterized by triacylglycerol accumulation in …

Obesity is a major public health problem and is related to increasing rates of cardiovascular
morbidity and mortality. Over 1.9 billion adults are overweight or obese worldwide and the …

Aims/hypothesis Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r)
agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the …

Objective Astrocytes actively participate in energy metabolism in the brain, and astrocytic
aerobic glycolysis disorder is associated with the pathology of Alzheimer's disease (AD) …

Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated
to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism …

Background/objectives The weight loss following Semaglutide treatment, a GLP-1 receptor
agonist, might be responsible for some effects observed on the nonalcoholic fatty liver …

Inflammation is implicated in the development and severity of the coronavirus disease 2019
(COVID-19), as well as in the pathophysiology of diabetes. Diabetes, especially when …

Early and effective glycemic control can prevent or delay the complications associated with
type 2 diabetes (T2D). The benefits of glucagon-like peptide-1 receptor agonists (GLP …

Given that obesity and diabetes have been major public health concerns and that disease
morbidities have been rising continuously, effective treatment for these diseases is urgently …

Abstract The effects of Endocrine Disrupting Chemicals (EDCs) on the current obesity
epidemic is a growing field of interest. Numerous EDCs have shown the potential to alter …